CPE Media News (4/18/2019) – Sanderling Ventures has made an undisclosed amount of investment in Tavec, Inc. As part of the investment, Tavec has redomiciled as TAVEC Pharmaceuticals and moved its head office from New York to Montreal. Therillia Development Co., an affiliate of Sanderling Ventures, will manage the investment.
Led by Dr. Fred Hochberg, Dr. Stephen J. Gould and Dr. Florin Selaru, TAVEC Pharmaceuticals is an early stage therapeutics company focused on developing the next generation of potent anti-cancer gene therapies using the power of injectable, miRNA loaded exosomes, packets of pinched off membrane which penetrate solid tumors, in particular liver cancers.
Tavec raised US $850,000 in seed funding in June 2015.
photo credit: TAVEC
THERILLIA acquires TAVEC Pharmaceutical and moves it to Montreal
MONTREAL, April 18, 2019 /CNW Telbec/ – Therillia Development Co., a Montreal-based subsidiary of Sanderling Ventures Canada, an investor in early-stage biotech companies, has acquired TAVEC Pharmaceuticals, the leading therapeutic exosome company and is moving its head office from New York to Montreal. Tavec is an early stage therapeutics company focused on developing the next generation of potent anti-cancer gene therapies using the power of injectable, miRNA loaded exosomes, packets of pinched off membrane which penetrate solid tumors, in particular liver cancers.
“We have developed a broad-based technology platform that has all the attributes required for multiple therapeutic applications,” says Stephen Gould, Ph.D. who, with Florin Selaru, M.D., are leading researchers in the field of exosomes and liver disease. Both are from Johns Hopkins University.
Created in New York in 2015, Tavec pharmaceuticals received seed funding and has successfully completed pre-clinical studies. It is currently working on developing its filings in Quebec to initiate clinical trials in liver cancers and chronic liver diseases. “We are very excited to be moving this unique technology into the clinic in the near future in Quebec,” indicated Dr. Fred Hochberg, one of the founders of TAVEC. Dr. Hochberg has had a distinguished career in medicine at Massachusetts General Hospital in Boston.
“Montreal offers one of the world’s most thriving ecosystems for developing biotech companies, including its globally renowned research institutions, rich pool of experienced drug developers and a cost-effective environment for developing important new therapeutics,” said Pierre Beauparlant, Ph.D., Chief Business Officer at Therillia. TAVEC is the eighth portfolio company Sanderling has established in Montreal under Therillia in the past five years.
Using Exosomes to Cure Liver Diseases
Exosomes are small vesicles, ~30–150 nm in diameter, produced by all cells and are a major means of cell-to-cell communication. The pioneering work of Gould, Selaru and Ling Li showed that specific types of these vesicles, prepared from select cell cultures, penetrate the stromal matrix of hepatic carcinomas and accumulate in the liver cancer cells. Moreover, injection of exosomes loaded with therapeutic RNAs has been shown to lead to the functional delivery of these RNAs to and into cancer cells, suppressing cancer in aggressive rodent liver cancer models. Furthermore, TAVEC’s proprietary exosome-RNA formulations appear to be effective in models of chronic liver disease, as described by Dr. Gould and Dr. Luke Boulter of Edinburgh University.
“The literature suggests that various forms of RNA can be effective therapeutic agents if they can be appropriately delivered to the needed site. The exosomes from the TAVEC preparations have shown that capability. This gives hope to the multitude of patients suffering from liver cancer,” said Dr. Hochberg.
Based in Montreal where it was created in 2013, Therillia Development Co. is a subsidiary of Sanderling Ventures, one of the oldest and most established North American venture firms focused exclusively on biomedical investing. Therillia’s mission is to benefit from Québec’s exceptional scientific and drug development potential to create medical therapies or medical device assets held by Sanderling portfolio companies. This model of “active management” utilizes the expertise of Therillia’s seasoned drug development team and has been successful in advancing multiple projects in a cost-effective manner. For more information, visit https://therillia.com
SOURCE Therillia Development Company Inc.
For further information: Guy Versailles, APR, FCPRS, Tel: +514 386 9774, firstname.lastname@example.org; Pierre Beauparlant, Ph.D., Chief Business Officer, Therillia Development Co., email@example.com, Tel: +514 564-6474 x 230